MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at EBMT’s 49th Annual Meeting
• The data was previously shared at the American Society of Hematology (ASH) Annual Meeting in December 2022. These include results for 81 patients with acute gastrointestinal graft-versus-host (aGvH) disease ( GI) treated with MaaT013 under the compassionate access program in France, as well as the results of the phase 1b CIMON trial evaluating MaaT033, Microbiome Ecosystem TherapyTM (MET) in oral capsule form in patients with myeloid leukemia acute (AML).
• The Company has been selected for two oral presentations as part of this congress: the presentations will detail the potential of MaaT013 and MaaT033 to improve the survival of patients with hematological malignancies.
To receive all of MaaT Pharma’s financial information in real time and for any questions, you can contact us via the following address: [email protected]